z-logo
open-access-imgOpen Access
Radiation Recall Pneumonitis in the Setting of Immunotherapy and Radiation: a Focused Review
Author(s) -
Kerri McGovern,
Maged Ghaly,
Michael Esposito,
Keara Barnaby,
Nagashree Seetharamu
Publication year - 2019
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.2144/fsoa-2018-0123
Subject(s) - pembrolizumab , pneumonitis , medicine , radiation therapy , radiation pneumonitis , context (archaeology) , immunotherapy , oncology , cancer , lung , biology , paleontology
Radiation recall pneumonitis (RRP) is an entity described as pneumonitis localized to a previously irradiated field after exposure to a systemic agent. It has previously been described in the literature in the context of chemotherapeutic agents as well as certain biologics. With immunotherapy taking a more prominent role in the treatment of several different malignancies and its own baseline risk of pneumonitis, it is important to explore the likelihood of RRP, specifically in those patients who have been previously treated with radiation therapy. The current literature regarding RRP with checkpoint inhibitors is reviewed in this article. Alongside this review, we report a case of RRP after pembrolizumab initiation in a patient in our practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom